Earnings Summary

Hsbc Holdings Plc’s revenue jumped 132.4% since last year same period to $38415Mn in the Q1 2024. On a quarterly growth basis, Hsbc Holdings Plc has generated 182.19% jump in its revenue since last 3-months.

Hsbc Holdings Plc’s net profit fell -1.5% since last year same period to $10584Mn in the Q1 2024. On a quarterly growth basis, Hsbc Holdings Plc has generated 37900% jump in its net profits since last 3-months.

Hsbc Holdings Plc’s net profit margin fell -57.61% since last year same period to 27.55% in the Q1 2024. On a quarterly growth basis, Hsbc Holdings Plc has generated 13495.06% jump in its net profit margins since last 3-months.

Hsbc Holdings Plc’s price-to-earnings ratio after this Q1 2024 earnings stands at 7.38.

Hsbc Holdings Plc’s earning per share (EPS) estimates for the current quarter stand at 1.6 - a 17.65% jump from last quarter’s estimates.

Hsbc Holdings Plc’s earning per share (EPS) estimates for the current year stand at 1.6.

Hsbc Holdings Plc’s earning per share (EPS) jumped 419.77% since last year same period to 2.7 in the Q1 2024. This indicates that the Hsbc Holdings Plc has generated 419.77% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Hsbc Holdings Plc’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Hsbc Holdings Plc’s return on equity (ROE) stands at 0.12.

Hsbc Holdings Plc declared 1.55 dividend per share during the earnings announcement for Q1 2024.